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ARCHIVAL REPORTAnhedonia and Reward-Circuit Connectivity
Distinguish Nonresponders from Responders to
Dorsomedial Prefrontal Repetitive Transcranial
Magnetic Stimulation in Major Depression
Jonathan Downar, Joseph Geraci, Tim V. Salomons, Katharine Dunlop, Sarah Wheeler,
Mary Pat McAndrews, Nathan Bakker, Daniel M. Blumberger, Zaﬁris J. Daskalakis,
Sidney H. Kennedy, Alastair J. Flint, and Peter GiacobbeBackground: Depression is a heterogeneous mental illness. Neurostimulation treatments, by targeting speciﬁc nodes within the brain’s
emotion-regulation network, may be useful both as therapies and as probes for identifying clinically relevant depression subtypes.
Methods: Here, we applied 20 sessions of magnetic resonance imaging-guided repetitive transcranial magnetic stimulation (rTMS) to
the dorsomedial prefrontal cortex in 47 unipolar or bipolar patients with a medication-resistant major depressive episode.
Results: Treatment response was strongly bimodal, with individual patients showing either minimal or marked improvement. Compared
with responders, nonresponders showed markedly higher baseline anhedonia symptomatology (including pessimism, loss of pleasure,
and loss of interest in previously enjoyed activities) on item-by-item examination of Beck Depression Inventory-II and Quick Inventory of
Depressive Symptomatology ratings. Congruently, on baseline functional magnetic resonance imaging, nonresponders showed
signiﬁcantly lower connectivity through a classical reward pathway comprising ventral tegmental area, striatum, and a region in
ventromedial prefrontal cortex. Responders and nonresponders also showed opposite patterns of hemispheric lateralization in the
connectivity of dorsomedial and dorsolateral regions to this same ventromedial region.
Conclusions: The results suggest distinct depression subtypes, one with preserved hedonic function and responsive to dorsomedial
rTMS and another with disrupted hedonic function, abnormally lateralized connectivity through ventromedial prefrontal cortex, and
unresponsive to dorsomedial rTMS. Future research directly comparing the effects of rTMS at different targets, guided by neuroimaging
and clinical presentation, may clarify whether hedonia/reward circuit integrity is a reliable marker for optimizing rTMS target selection.Key Words: Anhedonia, betweenness, depression, dorsomedial,
fMRI, graph theory, prefrontal, rTMS, stimulation, subtype
Major depression is heterogeneous in its course, sympto-matology, and responsiveness to treatment. A variety ofclinical features or biomarkers have been proposed to
reliably parse this heterogeneity into subtypes useful for prog-
nosis or treatment selection. Examples include Leonhard’s (1)
original distinction between unipolar and bipolar illness, as well
as later proposed distinctions between melancholic and atypical
depression (2), responsiveness to the dexamethasone suppression
test (3), and the presence of agitation or mixed features (4).
However, the utility of most such clinical features in guiding
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http://dx.doi.org/10.1016/j.biopsych.2013.10.026Anhedonia is a core symptom of depression in the DSM-IV
diagnostic criteria and is drawing increasing attention as a key
feature of the illness (5,6). Overall, studies using behavioral, pharma-
cologic, and neuroimaging methods suggest a disruption of the
appetitive and consummatory aspects of reward in depression
(7–11). However, its potential relevance to treatment selection
and outcome prediction has received relatively little attention
to date.
Current neuroimaging-based models of depression posit
network-level changes in the interactions between emotion-
regulating regions, including dorsomedial prefrontal cortex
(DMPFC) and ventromedial prefrontal cortex (VMPFC), dorso-
lateral prefrontal cortex (DLPFC) and ventrolateral prefrontal
cortex, and dorsal and ventral anterior cingulate cortex (ACC),
as well as amygdala, hippocampus, and brainstem monoaminer-
gic nuclei (12–17). The implications of this model are twofold:
ﬁrst, that different clinical subtypes of depressive illness could
arise from different patterns of network disruption, and second,
that different treatment modalities could target this network at
different points, thus addressing speciﬁc subtypes of illness.
Neuromodulation techniques, such as deep brain stimulation
(DBS) or repetitive transcranial magnetic stimulation (rTMS),
are neuroanatomically speciﬁc in their effects on brain activity.
Any putative network-level subtypes of depression might therefore
be most readily apparent with these treatment modalities. Deep
brain stimulation and rTMS may therefore be useful not only as
therapies but also as tools for parsing the heterogeneity of
depression in ways that are intrinsically relevant to treatment
selection.BIOL PSYCHIATRY 2014;76:176–185
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(18,19). However, convergent evidence from lesion, stimulation,
and neuroimaging studies (20) suggests that the DMPFC may also
play a central role in depression. Dorsomedial prefrontal cortex
lesions confer a strong risk of depressive symptoms (21,22).
Inadvertent deactivation of DMPFC via DBS can precipitate
immediate depressive symptomatology (23). The DMPFC also
shows consistent gray matter reduction in volumetric studies of
depression (24). Resting-state functional magnetic resonance
imaging (fMRI) studies have characterized the DMPFC as a dorsal
nexus region where networks for cognitive control, default-mode
rumination, and somatic marker generation converge in
depressed patients but not healthy control subjects (16). The
DMPFC may therefore present a promising target for excitatory
rTMS in depression (20), as suggested by a recent case report (25).
Aside from the dorsal nexus, other regions could potentially
contribute to the heterogeneity of depression. The mathematical
tools of graph theory, which enables detailed analysis of complex
network topology (26), are now being used to identify pathologic
patterns of brain activity in Alzheimer dementia, schizophrenia,
autism, and mood disorders (27–30). A particular network parameter,
known as betweenness centrality (BC), measures the number of
shortest paths between all other points A and B that pass through a
given node. Nodes with high BC act as chokepoints that can be
particularly damaging to network trafﬁc if they are disrupted.
Betweenness centrality maps have been used to identify
vulnerable points in energy transmission networks (31), critical
proteins in biochemical pathways for therapeutic targeting in
neurodegenerative disease (32,33), and abnormal patterns of
whole-brain functional connectivity in Alzheimer dementia (34).
Betweenness centrality has also recently been applied to resting-
state fMRI series to distinguish patients with depression from
healthy control subjects (35). However, to our knowledge, this
approach has never previously been used to distinguish res-
ponders from nonresponders to a given treatment.
In the present study, we ﬁrst sought to employ DMPFC-rTMS
as a probe, as well as a treatment, to test the hypothesis that this
intervention would reveal discrete subtypes of patients (as
opposed to a unimodal continuum of response) within a hetero-
geneous sample of patients with treatment-refractory depression.
Since virtually no studies of DMPFC-rTMS have been performed to
date, we then adopted a more descriptive approach, examining
pretreatment clinical and fMRI data to characterize the subtypes
in greater detail, both in terms of symptomatology and BC maps
of brain activity. Finally, we assessed the congruency of the
clinical-symptom outcome predictors with the neural activity
outcome predictors.Methods and Materials
Design Overview
This study investigated the effects of 20 sessions of open-label,
add-on bilateral magnetic resonance imaging (MRI)-guided rTMS
of the DMPFC in a series of patients meeting DSM-IV criteria for
unipolar or bipolar disorder and a current major depressive
episode resistant to medication. Following initial clinical assess-
ment, patients underwent MRI and a baseline symptom assess-
ment before motor threshold testing, then began treatment 3 days
later. During treatment, patients completed daily self-assessment
questionnaires and weekly clinician-rated assessments as described
below. Patients achieving response but not remission criteria were
offered an additional 10 sessions (2 weeks) of treatment. Patientsthen underwent clinical assessments at 2, 4, 6, 12, and 26 weeks
posttreatment to assess clinical response. Supplement 1 provides a
more detailed description of all methods used.
Subjects
Subjects were a series of 47 consecutive patients (20 male
patients, 27 female patients, age 42.2  12.7 years), with either
unipolar (n ¼ 38) or bipolar (n ¼ 9) illness referred to the
University Health Network’s MRI-Guided rTMS Clinic for the
treatment of a major depressive episode. All patients had a
clinical history of resistance to at least two adequate medication
trials (discontinuation of a medication trial due to adverse effects
also being included in this count), including at least one trial in
the current episode. Baseline symptom severity was a mean 22.7
 SD 6.8 on the 17-item Hamilton Rating Scale for Depression
(HAMD-17) and 32.6  SD 10.6 on the Beck Depression Inventory-
II (BDI-II). Major depressive episode duration was a mean 40.6
months  SD 55.7. The total number of previous medication trials
(including antidepressants and add-on mood stabilizers, antipsy-
chotics, or psychostimulants, discontinued due to either intoler-
ance or inefﬁcacy) ranged from 2 to 25 (mean 6.7  SD 4.3).
Seven patients had also previously failed to respond to electro-
convulsive therapy.
Regarding exclusion criteria, no patients with active substance
use or psychotic disorders participated in the study. Patients with
potential contraindications to rTMS or MRI, including a history of
seizures, implanted devices, foreign metal bodies, cardiac arrhyth-
mia, unstable medical conditions, or pregnancy, were excluded
from treatment. All patients had maintained a stable regimen of
medications for $4 weeks before treatment, with no changes
throughout the course of treatment. All patients provided
informed consent to treatment, and the study was approved by
the Research Ethics Board of the University Health Network.
rTMS Treatment Parameters
Repetitive transcranial magnetic stimulation was delivered
using a MagPro R30 rTMS device (MagVenture, Farum, Denmark)
via a Cool-DB80 stimulation coil. The coil vertex was placed over
the DMPFC under MRI guidance using the Visor 2.0 system
(Advanced Neuro Technologies, Enschede, The Netherlands).
The details of MRI acquisition, neuronavigation, and motor
threshold procedures are described in Supplement 1. Stimulation
was delivered at 120% of resting motor threshold, at 10 Hz, with a
duty cycle of 5 seconds on and 10 seconds off, for a total of 3000
pulses in 60 trains per hemisphere per session. Preferential
stimulation of each hemisphere was accomplished by lateral coil
orientation (36,37) (Figure 1A).
Clinical Assessments
In the week before treatment, before motor threshold testing,
patients underwent a baseline clinical assessment incorporating
the HAMD-17 as the primary outcome measure (38). Patients also
completed a battery of self-report BDI-II (39), Beck Anxiety
Inventory (40), 16-item self-rated Quick Inventory of Depressive
Symptomatology (QIDS) (41), Sheehan Disability Scale (42),
Quality of Life Enjoyment and Satisfaction Questionnaire (43),
and Warwick-Edinburgh Mental Well-Being Scale (44). This set of
clinician-rated and self-report assessments was repeated after
each ﬁve sessions of treatment, with follow-up assessments
scheduled 2, 4, 6, 12, and 26 weeks posttreatment. The Clinical
Global Impression of severity was also obtained before and after
treatment and the Clinical Global Impression-Improvement meas-
ure was collected posttreatment.www.sobp.org/journal
Figure 1. (A) Demonstration of placement of repetitive
transcranial magnetic stimulation coil for dorsomedial
prefrontal cortex stimulation with orientation of current
ﬂow to achieve preferential stimulation of the left
hemisphere. In this series, 3000 pulses of 10 Hz stimula-
tion at 120% resting motor threshold were applied to
left then right hemisphere at each session. (B) T1
anatomical magnetic resonance imaging scan with small
white square indicating the positioning of the coil vertex
in a representative subject. To achieve dorsomedial
prefrontal cortex coverage, the coil was placed at a
scalp location corresponding to the Talairach coordinate
(x 0, y 60, z 60), corresponding to 25% of the
nasion-inion distance.
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Resting-state functional neuroimaging data were preprocessed
using the FSL platform (45); six-regressor motion correction was
performed, and the CompCor package was applied to correct for
white matter and cerebrospinal ﬂuid noise sources (46). Differ-
ences in network activity among patients were then assessed
using a graph-theoretical approach. The approach is described in
greater detail in Supplement 1. To summarize, we ﬁrst applied the
resting-state connectivity-based atlas of Craddock et al. (47) to
each preprocessed fMRI series to deﬁne a set of 516 nodes, or
regions of interest (ROI), in the cortical and subcortical gray
matter. The time course of activity for each ROI was extracted and
used to generate a whole-brain cross-correlation matrix (Pearson’s
r). The Ledoit-Wolf shrinkage estimate was then used to generate
a partial correlation matrix (48,49), which was transformed to an
adjacency matrix with a sparsity of .1. This value achieved
maximum graph modularity, while at the same time avoiding
fragmentation of the graph into multiple subcomponents
(detailed methods in Supplement 1). This adjacency matrix was
then used to calculate a betweenness centrality measure for each
node using the MATLAB BGL toolbox (MathWorks, Natick, Massa-
chusetts) (Supplement 1). These values were then used to generate
a normalized map of whole-brain BC values for each subject. These
maps were used as the basis of between-subject comparisons, with
signiﬁcance testing via a 100,000-iteration Monte Carlo approach,
to identify ROIs showing signiﬁcant baseline differences in BC
between treatment responders versus nonresponders.Results
Clinical Outcomes
Clinical outcomes are summarized in Table 1. On the primary
outcome measure, HAMD-17, 24 of 47 patients (51.1%) achieved a
$50% reduction in symptoms and 20 of 47 patients (42.6%)
achieved the remission criterion of HAMD-17 #7 posttreatment.
On the secondary measure (BDI-II), outcomes were similar, with
23 of 47 patients (48.9%) reporting a $50% reduction in
symptoms and 21 of 47 patients (44.7%) achieving the remission
criterion of BDI -II #12 posttreatment. On continuous measures,
the group as a whole improved from 22.9  SD 7.0 before
treatment to 11.8  SD 9.3 posttreatment on the HAMD-17 (p 
.001) and 32.8  SD 10.7 to 19.9  SD 15.2 on the BDI-II (p www.sobp.org/journal.001) (Table 1). Symptomatic improvement proceeded approx-
imately linearly, week by week during treatment (Figure S1 in
Supplement 1).
Closer examination of the degree of improvement across
individuals, via kernel density estimation, revealed a bimodal
response distribution (Figure 2). Speciﬁcally, the probability
distribution function contained two peaks or subpopulations:
one with relatively little response to treatment (peak, 18%
improvement) and another subpopulation with a much more
robust response (peak, 84% improvement). The local minimum of
the probability distribution function between these two groups
lay at 48% improvement on HAMD-17, suggesting that the use of
a 50% response criterion did indeed provide an appropriate
segmentation between two distinct subpopulations and not
an arbitrary threshold on a single unimodal distribution of
response.
Given the presence of a bimodal distribution of outcomes,
additional separate analyses were carried out for responders and
nonresponders to quantify the degree and time course of
response among each group (Table 1). Among responders, scores
improved from 21.4  SD 6.7 pretreatment to 4.5  SD 3.8
posttreatment on the HAMD-17 and 27.8  SD 7.9 to 9.5  SD 7.2
on the BDI-II, representing a mean improvement from the
moderate to the remitted range of symptom severity (Table 1,
Figure 3).
Clinical Predictors of Outcome
To identify features of the clinical presentation that might
be predictive of outcome, baseline demographic, patient history,
and symptom scale measures were correlated to percentage
improvement in HAMD-17 scores from pretreatment to
posttreatment.
None of the seven electroconvulsive therapy refractory cases
achieved either response or remission on either the HAMD-17 or
the BDI-II. There was no signiﬁcant correlation between percent-
age improvement in HAMD-17 score and duration of current
episode (r ¼ .18; p ¼ .12), number of previous medication trials
(r ¼ .02; p ¼ .44), age (r ¼ .03; p ¼ .41), or gender (r ¼ .11; p ¼
.23). Nor was there any signiﬁcant difference in percent HAMD-17
improvement between patients with unipolar or bipolar illness
(t45 ¼ .05; p ¼ .96). Two of 2 patients with bipolar disorder, type I,
and 1 of 7 patients with bipolar disorder, type II, met HAMD-17
response criteria.
Table 1. Treatment Outcomes Overall and in Subgroups
Pretreatment Posttreatment
pMean SD Mean SD
Overall (n ¼ 47)
HAMD-17 22.9 7.0 11.8 9.3 .001
BDI-II 32.8 10.7 19.9 15.2 .001
BAI 21.3 14.6 13.2 14.4 .001
CGI 4.8 1.1 2.4 1.9 .001
SDS-Work 7.9 2.3 6.0 3.5 .001
SDS-Social 7.6 2.3 5.2 3.1 .001
SDS-Family 7.0 2.2 4.9 3.0 .001
SDS-Days Lost 3.5 2.8 2.6 3.0 .055
SDS-Days Unproductive 5.2 2.2 3.7 3.0 .003
WEMWBS 29.9 5.7 39.2 12.4 .001
QLESQ 32.5 6.4 41.1 12.1 .001
Responders (n ¼ 24)
HAMD-17 21.4 6.7 4.5 3.8 .001
BDI-II 27.8 7.9 9.5 7.2 .001
BAI 16.9 12.3 10.7 11.3 .001
CGI 4.4 .9 1.2 0.6 .001
SDS-Work 7.1 2.5 4.3 3.5 .001
SDS-Social 7.0 2.5 3.9 2.9 .001
SDS-Family 6.3 2.5 3.6 2.9 .001
SDS-Days Lost 3.5 3.1 1.4 2.6 .002
SDS-Days Unproductive 5.2 2.1 2.3 2.7 .001
WEMWBS 32.2 4.9 46.8 9.3 .001
QLESQ 34.5 6.0 48.7 9.6 .001
Nonresponders (n ¼ 23)
HAMD-17 24.5 7.1 19.4 6.8 .001
BDI-II 37.9 10.9 30.7 13.8 .001
BAI 25.9 15.6 15.9 17.0 .001
CGI 5.5 1.3 4.0 1.9 .037
SDS-Work 8.8 1.7 7.6 2.8 .055
SDS-Social 8.1 2.0 6.7 2.7 .037
SDS-Family 7.7 1.6 6.5 2.2 .017
SDS-Days Lost 3.5 2.5 3.9 2.9 .239
SDS-Days Unproductive 5.2 2.3 5.4 2.3 .687
WEMWBS 27.4 5.6 30.5 9.3 .014
QLESQ 30.3 6.2 32.9 8.9 .157
BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory-II; CGI,
Clinical Global Impression; HAMD-17, Hamilton Depression Rating Scale,
17 item; QLESQ, Quality of Life Enjoyment and Satisfaction Questionnaire;
SDS, Sheehan Disability Scale; WEMWBS, Warwick-Edinburgh Mental Well-
Being Scale.
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Figure 2. Probability distribution function for percent 17-item Hamilton
Rating Scale for Depression (HAMD-17) improvement from pretreatment
to posttreatment across the 47 patients in the series. The degree of
response was not unimodal but instead followed a sharply bimodal
distribution with a nonresponder group showing 15% to 25% improve-
ment and a responder group showing 80% to 90% improvement in
symptoms. The local minimum of the probability distribution lay almost
exactly at 50% improvement, suggesting that the original patient sample
of medication-resistant major depressive episode patients was appro-
priately partitioned by the conventional 50% improvement criterion into
distinct dorsomedial prefrontal cortex-repetitive transcranial magnetic
stimulation responder and nonresponder subpopulations.
J. Downar et al. BIOL PSYCHIATRY 2014;76:176–185 179To identify any speciﬁc symptoms that might predict outcome,
we then correlated HAMD-17 improvement to each of 115
individual items from the entire set of baseline symptom scales
(Table 2; Table S1 in Supplement 1). Following Bonferroni
correction for multiple comparisons (p  4.35  10−4), there were
three items that emerged as signiﬁcantly, negatively predictive of
HAMD-17 improvement: BDI-II item 2–pessimism (r ¼ .52; p ¼
6.47  10−5), BDI-II item 4–loss of pleasure (r ¼ .49, p ¼ 1.98 
10−4), and QIDS item 1–general interest (r ¼ .47; p ¼ 3.82  10−4).
The correlation between percent HAMD-17 improvement and the
normalized composite product of these measures was r ¼ .61
(p ¼ 1.29  10−6) (Figure 3B).
No individual items on HAMD-17, Quality of Life Enjoyment
and Satisfaction Questionnaire, or Warwick-Edinburgh Mental
Well-Being Scale signiﬁcantly predicted outcome. Likewise, at
the Bonferroni-adjusted threshold, there was no signiﬁcant
predictive correlation to outcome for overall baseline score onthe BDI-II (r ¼ .42; p ¼ ns), HAMD-17 (r ¼ .20; p ¼ ns), or QIDS
(r ¼ .45; p ¼ ns) (Table 2; Table S1 in Supplement 1).
Neuroimaging Predictors of Outcome
As a preliminary, ﬁrst-pass assessment of the physiological
relevance of the BC-mapping approach, we identiﬁed the set of
regions in the upper ﬁfth percentile (two-tailed) of BC difference
between responders and nonresponders (Table S2 and Figures S2
and S3 in Supplement 1). This set of regions corresponded well to
the network of regions previously implicated in depression and
emotional reappraisal (12,14,50,51). Speciﬁcally, responders
showed signiﬁcantly higher BC than nonresponders in right
amygdala, ventral striatum, temporal pole, and DMPFC, as well
as a region in left DLPFC and anterior insula. Nonresponders
showed signiﬁcantly higher BC than responders in left VMPFC, as
well as regions in left DLPFC, DMPFC, dorsal ACC, retrosplenial
cingulate cortex, and right anterior insula. Thus, the BC approach
did appear successful in localizing predictive differences to a set
of regions with plausible involvement in emotion regulation.
(Figure 4B).
We next applied to this map a more stringent threshold,
Bonferroni-corrected for multiple comparisons as with the clinical
measures, across the 516 regions of interest. At this threshold,
only the node in left VMPFC at Montreal Neurological Institute
coordinate (x 4, y 48, z 15) showed markedly higher BC in
nonresponders than in responders to treatment (p ¼ .00001). This
result was robust across a range of graph sparsities from .1 to .5,
assessed in increments of .02, suggesting a relative lack of
contingency on the choice of connectivity threshold (Figure S6
in Supplement 1). Of note, this speciﬁc VMPFC region corre-
sponded very closely to the VMPFC region previously identiﬁed in
neuroimaging meta-analyses as activated for a wide variety of
rewarding stimuli in healthy control subjects (52,53) (Figure 4B).www.sobp.org/journal
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Figure 3. (A) Trajectories of improvement in responder and nonresponder subpopulations. Responders showed a steady improvement to meet the
remission criterion of 17-item Hamilton Rating Scale for Depression (HAMD-17) score #7 over the course of treatment, while nonresponders showed
minimal improvement. (B) The normalized product of pretreatment scores on three anhedonia-related items (Beck Depression Inventory-II item 2, Beck
Depression Inventory-II item 4, and Quick Inventory of Depressive Symptomatology item 13) was a strong negative predictor of percentage improvement
in HAMD-17 score from pretreatment to posttreatment.
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this region in responders and nonresponders, we performed a
statistical comparison of the whole-brain resting-state connectivity
of this left VMPFC region with the other 515 regions across the
two groups (whole-brain false discovery rate-corrected p  .05)
(Table 3, Figure 4C,D). Compared with responders, nonresponders
showed signiﬁcantly lower connectivity to left VMPFC in the
ventral tegmental area and left caudate nucleus. They also showed
lower signiﬁcant connectivity to left VMPFC in a left-lateralized set
of cortical regions that included the left DMPFC, DLPFC, inferiorTable 2. Clinical Predictors of Outcome
Symptom
Scale Item
Correlation to
% HAMD-17
Improvement p
BDI-II Pessimism .520 6.47  10−5
Loss of pleasure .488 1.98  10−4
QIDS General interest .468 3.82  10−4
Other QIDS - Total .448 ns
HAMD-17 - Total .204 ns
Age .033 ns
Gender .110 ns
Episode duration .177 ns
# Failed medicine trials .022 ns
Unipolar/bipolar .007 ns
All signiﬁcantly predictive items were identiﬁed using a threshold p 
.05, Bonferroni-corrected for multiple comparisons across the 115 items
surveyed in the baseline mood and functional scales (i.e., threshold p ¼
4.35  10−4).
HAMD-17, Hamilton Depression Rating Scale, 17 item; BDI-II, Beck
Depression Inventory-II; ns, nonsigniﬁcant; QIDS, Quick Inventory of
Depressive Symptomatology–Self-rated 16-item scale.
www.sobp.org/journalparietal lobule, and anterior insula. In addition, compared with
responders, nonresponders showed higher connectivity to left
VMPFC in a corresponding right-lateralized set of cortical regions
that included right DMPFC and DLPFC, as well as right frontopolar
cortex and posterior cingulate cortex (Table 3, Figure 4C,D).
Discussion
To our knowledge, this is the ﬁrst report on either the
effectiveness or predictors of outcome for DMPFC-rTMS in a
series of patients with a medication-resistant major depressive
episode. The results of the present study suggest that the patients
did not respond uniformly to treatment but instead showed a
strongly bimodal separation into a responder and a nonresponder
group (Figure 2). The implication is that the original sample of
patients, though all meeting criteria for a major depressive
episode, may have comprised at least two distinct subgroups
rather than a uniform and homogeneous population. Of note, a
similar bimodal heterogeneity of response has recently been
described in meta-analyses of clinical trials for duloxetine (54) and
escitalopram (55).
Examination of the pretreatment clinical symptomatology
conﬁrmed a set of predictive differences between eventual
responders and nonresponders at a high level of signiﬁcance.
The predictive items concurred across two independent scales
(BDI-II and QIDS) and could potentially represent pathology of the
appetitive and consummatory aspects of reward: pessimism
(appetitive), general interest in formerly enjoyed activities (appe-
titive), and loss of pleasure (consummatory). The former two
symptoms, in combination, have been observed elsewhere to be
associated in major depression (56).
More strikingly, the neuroimaging results were congruent with
the clinical predictors in identifying a single, speciﬁc VMPFC
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Figure 4. Neuroimaging correlates of response to dorsomedial prefrontal cortex (DMPFC)-repetitive transcranial magnetic stimulation. A comparison of
betweenness centrality values in nonresponders versus responders to treatment revealed a single region whose betweenness centrality was signiﬁcantly
higher in nonresponders (A). This region lay in left ventromedial prefrontal cortex (VMPFC), at a location similar to that observed in previous meta-
analyses of reward- versus loss-related activation in healthy control subjects (B) [reprinted from Diekhof et al. (53) with permission from Elsevier, copyright
2012]. Compared with responders, nonresponders showed signiﬁcantly lower functional connectivity between the VMPFC seed and the ventral tegmental
area and striatum, as well as between the VMPFC seed and a left-lateralized network of cortical regions including left DMPFC, dorsolateral prefrontal cortex
(DLPFC), and anterior insula (C,D). Conversely, nonresponders showed signiﬁcantly higher functional connectivity from the VMPFC seed to a right-
lateralized network of cortical regions including right DMPFC, DLPFC, and posterior cingulate cortex.
J. Downar et al. BIOL PSYCHIATRY 2014;76:176–185 181region, previously shown to activate consistently for rewarding
stimuli across a wide variety of studies, as predictive of treatment
outcome. This region showed higher BC in nonresponders, and
thus could potentially be considered as a bottleneck region in
depressed patients with anhedonia and nonresponsiveness to
dorsomedial stimulation. In nonresponders, this region showed
signiﬁcantly lower connectivity to a circuit of dopaminergic
regions, including the ventral tegmental area and left caudate
nucleus, suggesting a disruption of the reward pathway, which
would be in keeping with the clinical features of this
subpopulation.
There was also a striking hemispheric asymmetry in the set of
brain regions showing connectivity to the left VMPFC seed in
responders versus nonresponders. Nonresponders had signiﬁ-
cantly higher functional connectivity to left VMPFC from a set
of right-lateralized regions, including right DMPFC, DLPFC, fron-
topolar cortex, posterior cingulate cortex, and middle temporalgyrus. In contrast, they showed signiﬁcantly lower functional
connectivity to left VMPFC from a similar but left-lateralized set of
regions including left DMPFC, DLPFC, caudate nucleus, inferior
parietal lobule, and occipital cortex. We also note a left-
hemispheric lateralization of the VMPFC seed region itself, in
contrast to the bilateral reward-related activity seen in studies in
healthy control subjects (52,53).
The distinct and opposite lateralized pattern of left VMPFC
connectivity in responders versus nonresponders was rather
striking and bears further consideration. On one view, a deﬁcit
in left hemisphere connectivity to ventral prefrontal regions in
nonresponders could be considered consistent with the original
rationale for targeting left DLPFC in the ﬁrst studies of excitatory
rTMS for major depression (57,58) to address hypoactivity of left
prefrontal regions. This perspective would suggest the possibility
of achieving further gains in rTMS efﬁcacy by tailoring the
laterality and frequency of rTMS to the individual patient basedwww.sobp.org/journal
Table 3. Regions with Higher Signiﬁcant Pretreatment Functional Connectivity to the Identiﬁed VMPFC Region in Responders Versus Nonresponders
Brodmann
MNI Coordinates Signiﬁcance
Region Area x y z Z p
L VMPFC Connectivity: Responders  nonresponders
L caudate nucleus – 14 20 0 6.51 7.63  10−11
– 14 14 9 2.75 3.00  10−3
Ventral tegmental area – 1 26 6 5.63 9.22  10−9
– 6 18 13 4.38 5.81  10−6
– 8 19 13 3.73 9.47  10−5
Pons – 6 28 39 5.21 9.68  10−8
– 3 22 33 2.59 4.82  10−3
L dorsomedial prefrontal cortex 8 11 32 56 3.66 1.24  10−4
9 45 46 3.21 6.64  10−4
L dorsolateral prefrontal cortex 9 44 13 45 3.65 1.31  10−4
9 37 20 52 3.52 2.14  10−4
L occipital cortex 19 31 66 13 3.49 2.44  10−4
L inferior parietal lobule 39/40 50 54 44 3.36 3.92  10−4
39/40 56 52 33 2.80 2.55  10−3
40 39 47 55 2.81 2.51  10−3
L cerebellum – 38 43 33 3.33 4.27  10−4
L anterior insula – 35 25 5 3.13 8.77  10−4
R occipital cortex 18 31 88 4 4.25 1.09  10−5
R anterior insula – 29 21 6 3.58 1.73  10−4
R precuneus 7 4 65 40 3.18 7.25  10−4
L VMPFC Connectivity: Nonresponders  responders
R fusiform gyrus 37 35 52 17 3.99 3.31  10−5
R dorsolateral prefrontal cortex 9 28 33 36 3.69 1.13  10−4
46 29 45 28 3.26 5.57  10−4
6 40 1 53 2.91 1.81  10−3
R posterior cingulate cortex 23 5 39 39 3.11 9.20  10−4
R middle temporal gyrus 20 61 26 12 3.08 1.02  10−3
R dorsomedial prefrontal cortex 9 7 50 42 2.96 1.55  10−3
9 6 58 30 2.81 2.49  10−3
R frontopolar cortex 10 19 67 9 2.91 1.82  10−3
L middle cingulate cortex 24 2 3 34 4.25 1.08  10−5
L middle paracingulate cortex 32 7 12 42 3.36 3.86  10−4
All activations were identiﬁed using a threshold p  .05, Bonferroni-corrected for multiple comparisons across the 515 cross-correlations performed
between the VMPFC region and each other region of interest in the atlas (i.e., threshold p ¼ 9.67  10−5). Images of identiﬁed regions are presented in
Figure 4B.
L, left; MNI, Montreal Neurological Institute; R, right; VMPFC, ventromedial prefrontal cortex.
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VMPFC or other associated regions such as the amygdala.
Alternatively, the observed pattern of lateralization could poten-
tially reﬂect the larger proportion of female subjects in the
present study: previous studies have identiﬁed a gender-
dependent hemispheric asymmetry in which female subjects
preferentially activate left hemisphere VMPFC (as well as amyg-
dala, hippocampus, and ACC) in response to negative stimuli,
while male subjects preferentially activate these regions for
positive stimuli (59,60). In addition, previous observations of left-
and right-hemisphere specialization for control of the parasym-
pathetic and sympathetic nervous systems, respectively, may also
be of relevance in interpreting the lateralized results observed in
the present study (61).
The lack of response to treatment among a subgroup of
patients in the present study could also potentially reﬂect the
deep anatomical location of the VMPFC region, beyond the reach
of the ﬁeld applied during DMPFC-rTMS. This hypothesis gen-
erates three testable predictions: stimulation of the VMPFC region
should also be effective in a subgroup of depressed patients; thiswww.sobp.org/journalsubgroup should be characterized by prominent anhedonic
symptoms before treatment; and these anhedonic symptoms
should improve with stimulation.
While rTMS has not yet been applied to the VMPFC in this
setting, two independent groups have targeted this pathway in
depression using DBS, applied either to the subgenual ACC
(62,63) or the nucleus accumbens (64). In both cases, neuro-
imaging investigations revealed DBS to deactivate precisely the
VMPFC region identiﬁed in the present study (63,64). With DBS of
the nucleus accumbens, hedonic response improved signiﬁcantly
overall, and responders showed long-term improvements in
pursuit of positive activities (65). With DBS of the subgenual
ACC, higher baseline symptoms of anhedonia predicted better,
rather than poorer, treatment response—the opposite pattern
from dorsomedial stimulation based on the results of the present
study (66).
In the context of previous neuroimaging studies suggesting
dorsomedial hypoactivity and ventromedial hyperactivity in major
depression (12,67), the results of this study and the results of the
DBS studies suggest that there may exist at least two distinct
J. Downar et al. BIOL PSYCHIATRY 2014;76:176–185 183depression subtypes: a dorsal-hypoactive type, responsive to
DMPFC-rTMS and characterized by preserved hedonic response,
and a ventral-hyperactive type, responsive to DBS of VMPFC
reward pathways and characterized by disrupted hedonic
response. This hypothesis would be consistent with the lesion
and volumetric literature associating vulnerability to depression
with injury/gray matter reduction in DMPFC and protective effects
against depression with injury/gray matter reduction in VMPFC
(22,24).
A signiﬁcant limitation of the present study involves the use of
an open-label design without sham stimulation. Such a design
cannot precisely quantify the speciﬁc versus the nonspeciﬁc
effects of treatment suing DMPFC-rTMS. For context, it should
be kept in mind that a recent meta-analysis quantiﬁed the
response and remission rates for sham DLPFC-rTMS at only 10%
and 5%, respectively, with the response and remission rates for
active DLPFC-rTMS at 29.3% and 18.6%, respectively (68). Thus, it
would be difﬁcult to account for the present study’s observed
response and remission rates of 51% and 43%, respectively, as due
entirely to sham effects. However, a randomized, sham-controlled
trial of DMPFC-rTMS will be an essential follow-up to the present
open-label case series in establishing the effectiveness of this
stimulation target. A blinded comparison of the efﬁcacy of DMPFC-
rTMS and DLPFC-rTMS might also be worth pursuing in the future.
Other signiﬁcant limitations include the use of a relatively
small sample size and the availability of functional neuroimaging
in only a subset of patients. This leaves open the possibility that
additional signiﬁcant predictors of outcome might reveal them-
selves in a larger or a more standardized sample. For example, the
considerable heterogeneity of medication classes and doses in
this sample precluded any determination of whether medication
type or dose might be predictive of outcome, and this remains an
open question for more systematic study in the future.
The present study also does not clarify whether hedonic
response and reward-circuit integrity are also distinguishing
features for responders versus nonresponders to rTMS of the
conventional target, DLPFC. Symptoms of apathy have been
reported to predict nonresponse to DLPFC-rTMS using a deep
stimulation coil, suggesting the possibility of such a relationship
(69). The generalizability of the present results to DLPFC-rTMS
remains an important question for further study.
In conclusion, the search for clinically meaningful subtypes of
major depression is now beginning to proﬁt from recent
advances in understanding major depression as a network-level
pathology of connectivity among emotion-regulating regions of
the brain. Anatomically targeted therapies, such as rTMS and DBS,
may be particularly well-suited to individualized treatment based
on clinical presentation. Stimulation studies now appear to be
consistent with lesion studies in identifying DMPFC and VMPFC as
playing central, yet complementary, roles in the pathophysiology
of depression. Further studies comparing the effects of stimula-
tion at these two sites, in individual patients, will clarify whether
this distinction is robust and clinically meaningful. If so, the long-
recognized core depression symptom of anhedonia, and its
underlying neural correlates, may prove themselves to be reliable
guides for maximizing the likelihood of successful treatment in
patients with otherwise intractable illness.
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